{"id":"spmc-2","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"10-20%","effect":"Headache"},{"rate":"5-10%","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By binding to S1PR1, SPMC 2 inhibits the migration of lymphocytes to lymphoid organs, thereby reducing inflammation and modulating immune responses. This mechanism of action is thought to be beneficial in the treatment of autoimmune diseases.","oneSentence":"SPMC 2 is a small molecule that targets the Sphingosine-1-phosphate receptor 1 (S1PR1) to modulate immune responses.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:35:57.899Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Multiple sclerosis"}]},"trialDetails":[{"nctId":"NCT07206329","phase":"NA","title":"PEG-Asc Vs. SPMC for Bowel Preparation in Capsule-based Procedures","status":"COMPLETED","sponsor":"Unidade Local de Saúde do Alto Ave, EPE","startDate":"2024-01-01","conditions":"Bowel Preparation Solution","enrollment":220},{"nctId":"NCT04474002","phase":"PHASE4","title":"Efficacy, Tolerance and Safety of Split Dose Bowel Preparation for Colonoscopy: 4L Polyethylene Glycol (PEG) Versus 1L Polyethylene Glycol Plus Sodium Picosulfate-magnesium Citrate (SPMC)","status":"COMPLETED","sponsor":"Queen Elizabeth Hospital, Hong Kong","startDate":"2020-12-07","conditions":"Bowel Preparation Solutions, Colonoscopy","enrollment":158},{"nctId":"NCT03965182","phase":"NA","title":"Compare Polyethylene Glycol and Sodium Picosulfate Alone or Combined","status":"UNKNOWN","sponsor":"Dalin Tzu Chi General Hospital","startDate":"2019-06-01","conditions":"Bowel Preparation","enrollment":600},{"nctId":"NCT02908919","phase":"PHASE4","title":"Impact of Time Intervals of Preparation on Quality and Tolerance of the Bowel Preparation","status":"UNKNOWN","sponsor":"Faculty Hospital Kralovske Vinohrady","startDate":"2016-08","conditions":"Bowel Preparation, Colonoscopy","enrollment":480},{"nctId":"NCT02250196","phase":"PHASE3","title":"A Randomized Prospective Trial Comparing Low-volume Bowel Preparation Methods","status":"COMPLETED","sponsor":"Korea University Anam Hospital","startDate":"2013-03","conditions":"Colorectal Cancer, Colon Adenoma","enrollment":200},{"nctId":"NCT01778192","phase":"PHASE3","title":"A Randomized Prospective Trial Comparing Polyethylene Glycol and Sodium Picosulphate With Magnesium Citrate","status":"COMPLETED","sponsor":"Korea University Anam Hospital","startDate":"2012-07","conditions":"Colorectal Cancer, Colon Adenoma","enrollment":200}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":59,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Picolight(Pharmbio korea, Seoul, Korea)"],"phase":"phase_3","status":"active","brandName":"SPMC 2","genericName":"SPMC 2","companyName":"Korea University Anam Hospital","companyId":"korea-university-anam-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"SPMC 2 is a small molecule that targets the Sphingosine-1-phosphate receptor 1 (S1PR1) to modulate immune responses. Used for Multiple sclerosis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}